FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left-Sided <i>RAS/BRAF</i> Wild-Type Colorectal Cancer: Which “Side” Are You On?

Yu, Irene S.; Loree, Jonathan M.

doi:10.1002/onco.13705

Cited by 1 publication

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, there is less consensus regarding the proportion of patients who should receive first-line targeted therapies for metastatic CRC. Regimens containing cetuximab and panitumumab are associated with more modest benefits, and there remains uncertainty about when they are superior to alternatives …”

Section: Discussionsupporting

confidence: 81%

“…Regimens containing cetuximab and panitumumab are associated with more modest benefits, and there remains uncertainty about when they are superior to alternatives. [38][39][40] Nonetheless, universal molecular testing has been recommended for both metastatic CRC and nonsquamous NSCLC since 2011. The increases in molecular testing seen for both NSCLC and CRC are encouraging; however, rates for both cancers remained low.…”

Section: Discussionmentioning

confidence: 99%

“…Regimens containing cetuximab and panitumumab are associated with more modest benefits, and there remains uncertainty about when they are superior to alternatives. 38 , 39 , 40 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Practice-Level Variation in Molecular Testing and Use of Targeted Therapy for Patients With Non–Small Cell Lung Cancer and Colorectal Cancer

et al. 2023

View full text Add to dashboard Cite

ImportanceAll patients with newly diagnosed non–small cell lung cancer (NSCLC) and colorectal cancer (CRC) should receive molecular testing to identify those who can benefit from targeted therapies. However, many patients do not receive recommended testing and targeted therapies.ObjectiveTo compare rates of molecular testing and targeted therapy use by practice type and across practices.Design, Setting, and ParticipantsThis cross-sectional study used 100% Medicare fee-for-service data from 2015 through 2019 to identify beneficiaries with new metastatic NSCLC or CRC diagnoses receiving systemic therapy and to assign patients to oncology practices. Hierarchical linear models were used to characterize variation by practice type and across practices. Data analysis was conducted from June 2019 to October 2022.ExposuresOncology practice providing care.OutcomesPrimary outcomes were rates of molecular testing and targeted therapy use for patients with NSCLC and CRC. Secondary outcomes were rates of multigene testing for NSCLC and CRC.ResultsThere were 106 228 Medicare beneficiaries with incident NSCLC (31 521 [29.7%] aged 65-69 years; 50 348 [47.4%] female patients; 2269 [2.1%] Asian, 8282 [7.8%] Black, and 91 215 [85.9%] White patients) and 39 512 beneficiaries with incident CRC (14 045 [35.5%] aged 65-69 years; 17 518 [44.3%] female patients; 896 [2.3%] Asian, 3521 [8.9%] Black, and 32 753 [82.9%] White patients) between 2015 and 2019. Among these beneficiaries, 18 435 (12.9%) were treated at National Cancer Institute (NCI)–designated centers, 8187 (5.6%) were treated at other academic centers, and 94 329 (64.7%) were treated at independent oncology practices. Molecular testing rates increased from 74% to 85% for NSCLC and 45% to 65% for CRC. First-line targeted therapy use decreased from 12% to 8% among patients with NSCLC and was constant at 5% for patients with CRC. For NSCLC, molecular testing rates were similar across practice types while rates of multigene panel use (13.2%) and targeted therapy use (16.6%) were highest at NCI-designated cancer centers. For CRC, molecular testing rates were 3.8 (95% CI: 1.2-6.5), 3.3 (95% CI, 0.4-6.1), and 12.2 (95% CI, 9.1-15.3) percentage points lower at hospital-owned practices, large independent practices, and small independent practices, respectively. Rates of targeted therapy use for CRC were similar across practice types. After adjusting for patient characteristics, there was moderate variation in molecular testing and targeted therapy use across oncology practices.Conclusions and RelevanceIn this cross-sectional study of Medicare beneficiaries, molecular testing rates for NSCLC and CRC increased in recent years but remained lower than recommended levels. Rates of targeted therapy use decreased for NSCLC and remained stable for CRC. Variation across practices suggests that where a patient was treated may have affected access to recommended testing and efficacious treatments.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 99%